PLEASANTON, Calif., June 10, 2011 /PRNewswire/ — Thoratec
THOR), a world leader in device-based mechanical circulatory
support therapies to save, support and restore failing hearts,
announced today that David V. Smith, Executive Vice President and
Chief Financial Officer, has resigned from his position in order to
pursue other business opportunities. Mr. Smith will remain
with Thoratec through July 1st and assist in the transition
“Over the past several years, David has played a key role in
building a world-class financial infrastructure at Thoratec, which
positions the company well to support continued strong performance.
We thank him for his contributions and wish him well in his
future endeavors,” said Gary F. Burbach, President and Chief
In conjunction with today’s announcement, Thoratec is
reiterating its previously issued 2011 financial guidance.
Roxanne Oulman, Vice President of Finance, will serve as interim
Chief Financial Officer until a permanent replacement is named.
Ms. Oulman joined Thoratec in 2004 and has assumed increasing
levels of responsibility since that time.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company’s products include the
HeartMate® LVAS (Left Ventricular Assist System) and
Thoratec® VAD (Ventricular Assist Device) with more than 18,000
devices implanted in patients suffering from heart failure.
Thoratec is headquartered in Pleasanton, California. For more
information, visit the company’s website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation.
Many of the preceding paragraphs, particularly but not
exclusively those addressing guidance for fiscal 2011 finan